News

 

NMS-01940153E (NMS-153) at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

NMS-01940153E (NMS-153) at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

A week from the presentation of Nerviano Medical Sciences S.r.l. (a member of NMS Group) on NMS-01940153E (NMS-153) at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, we’re thrilled to share the official press release from ENA 2022 of NMS-153. A highly potent and selective inhibitor of the MPS1 kinase, NMS-153 is a mitotic regulator frequently overexpressed and activated in cancer. NMS-153 showed a broad preclinical activity in different tumor types, including HCC. Please read the press release here! 
(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. names Salvatore Marengoni Galdy, M.D., Global Clinical Lead

Nerviano Medical Sciences S.r.l. names Salvatore Marengoni Galdy, M.D., Global Clinical Lead

NMS today announced that Salvatore Marengoni Galdy, M.D., has joined the Global Clinical Development Team as Global Clinical Lead, effective immediately. Dr. Galdy will drive values of our assets through planning and leading the clinical development to meet all time, quality, budget, Company standards and scientific requirements.
(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. Shared Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 

Nerviano Medical Sciences S.r.l. Shared Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 

Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today shared data from the Company’s Phase I/II clinical study of NMS-01940153E in Hepatocellular carcinoma (HCC) in an oral presentation by Dr. Maria Reig at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics  (ENA 2022)  in Barcelona.
(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. Announces a Poster Presentation on NMS-03602173 at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Nerviano Medical Sciences S.r.l. Announces a Poster Presentation on NMS-03602173 at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that preclinical data from the Company’s asset NMS-03602173 will be reported in a poster presentation by Dr. Paola Magnaghi at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics  (ENA 2022)  which will be held October 26-28, 2022 at the CCIB in Barcelona.
(Click the title for the complete article)

NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR

NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR

NERVIANO, 18 October 2022 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that data from the Company’s Phase I/II clinical study of NMS-01940153E in Hepatocellular carcinoma (HCC) will be reported in an oral presentation by Dr. Maria Reig at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics  (ENA 2022)  which will be held October 26-28, 2022 at the CCIB in Barcelona.
(Click the title for the complete article)

NMS Group S.p.A. Appoints Andrew Curtis as Chief Strategy Officer, Effective Immediately

NMS Group S.p.A. has announced the appointment of Andrew Curtis as Chief Strategy Officer reporting to the Group CEO, effective immediately. Andrew brings to NMS Group three decades of experience as a global corporate strategy and business leader from biotech and pharma sectors. He is based in the US, working from the US subsidiary (Nerviano Medical Sciences Inc.) in Boston just opened this month.
(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. Expands US Presence

Nerviano Medical Sciences S.r.l. (NMS Srl), announced today that it has expanded its presence in the US with the creation of a new US subsidiary, Nerviano Medical Sciences Inc. Nerviano Medical Sciences Inc. is incorporated in Delaware State while the company’s activities will be mostly concentrated in the Boston, Massachusetts area. The US subsidiary is part of NMS Srl and its holding NMS Group’s aggressive transformation plan to fortify further the Group’s footprint and accelerate its pace in expanding in the world’s key biotech and pharmaceutical market.
(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. Announces First Patient Dosed in Phase 1 Clinical Trial of NMS-812 for The Treatment of Relapsed Refractory Multiple Myeloma (MM).

NMS-812 is a novel potent oral inhibitor of PERK (PKR-like endoplasmic reticulum kinase) that also inhibits GCN2 (General Control Nonderepressible 2). PERK and GCN2 are effectors of the Integrated Stress Response (ISR), a pro-survival pathway exploited by cancer cells to survive stress. PERK is a key effector of the unfolded protein response (UPR) and GCN2 is a sensor of amino acid deficiency. Both proteins modulate the eIF2α/ATF4 axis promoting tumor survival and drug resistance as well as, via direct and indirect mechanisms, the immune response.
(Click the title for the complete article)

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO